Organisation paid for research Program year 2025 Source: CMS Open Payments

Core Inc

Neither a doctor nor a teaching hospital

Research payments

$871,952

45 payments

Through program year 2025, Core Inc is reported as receiving $871,952 in research payments, across 45 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$150,046	7
2023	Research	$214,246	13
2022	Research	$70,200	3
2021	Research	$399,135	16
2020	Research	$38,325	6

Breakdown

Who paid Research payments · program years 2020–2025

Alcon Research LLC $434,118 22 payments
Aerie Pharmaceuticals, Inc. $414,360 19 payments
Mallinckrodt Hospital Products Inc. $23,100 3 payments
AbbVie, Inc. $375 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease $371,210 11 payments
Long-term evaluation of safety and performance of Clareon Presbyopia-Correction IOLs PMCF Study of Clareon Vivity and Clareon PanOptix $212,945 12 payments
COMET-Ocular Surface Characteristics Study $127,631 5 payments
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $70,200 3 payments
Ophthalmic Assessments of Signs and Symptoms of Dry Eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease $43,150 8 payments
A Multicenter, Open-Label Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Severe Keratitis $23,100 3 payments
COMET-Basal Tear Study $22,041 1 payment
A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-2) $1,301 1 payment
A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation with REFRESH OPTIVE Unit Dose in Patients with Dry Eye Disease $375 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.